Medtronic plc's Stock Analysis

Medtronic Executive Vice President to Retire in December 2025

Gregory L. Smith, the Executive Vice President of Enterprise Operations at Medtronic plc, has announced his retirement effective December 2, 2025. Following his retirement, he will join a private equity-held organization.

Upon retirement, Mr. Smith will receive retirement treatment for his outstanding equity compensation. This includes the acceleration of unvested stock options and continued vesting of restricted stock units and performance stock units, as outlined in the company's previous filings.

Nov 03, 2025 17:21:46

Medtronic Shareholders Approve Key Amendments and Director Elections

Medtronic plc held its Annual General Meeting on October 16, 2025, where shareholders approved several important amendments to the Company's Articles of Association. These amendments included changes to authorize the Board of Directors to capitalize certain non-distributable reserves and updates to the advance notice provisions. The meeting also involved the election of twelve directors to serve until the 2026 Annual General Meeting and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026.

In addition to the director elections and auditor ratification, shareholders approved various proposals including the renewal of the Board's authority to issue shares and opt out of pre-emption rights. The Company was also authorized to make overseas market purchases of its ordinary shares. A capital reduction was approved to create distributable reserves under Irish law. The meeting had a quorum with over 1.1 billion ordinary shares represented, ensuring that all votes were validly cast.

Oct 21, 2025 16:16:47

Medtronic Issues €1.49 Billion in Senior Notes Offering

Medtronic, Inc., a subsidiary of Medtronic plc, has issued €750 million in 2.950% Senior Notes due 2030 and €750 million in 4.200% Senior Notes due 2045. The offering is expected to generate net proceeds of approximately €1.49 billion, which will be used to repay existing senior notes maturing in 2025. The Notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, and have been approved for listing on the New York Stock Exchange.

The Notes will mature on October 15, 2030, and October 15, 2045, respectively, and will have general unsecured senior obligations ranking equally with other existing senior indebtedness. Medtronic, Inc. retains the option to redeem the Notes prior to their maturity under specified conditions. Additionally, the redemption of €500 million of existing senior notes due 2025 was executed on the same date as the issuance of the new Notes, contingent upon the successful completion of this offering.

Sep 29, 2025 08:45:28

Medtronic Announces Senior Notes Offering and Redemption Plan

On September 15, 2025, Medtronic plc announced the pricing of an offering to issue €750 million in 2.950% Senior Notes due 2030 and €750 million in 4.200% Senior Notes due 2045. The net proceeds from this offering are intended to be used to repay existing 0.000% and 2.625% Senior Notes due 2025. This financial activity is reflected in the company's fiscal year 2026 adjusted earnings per share guidance previously reiterated on August 19, 2025.

Additionally, Medtronic Luxco has elected to redeem all €500 million of its outstanding 2.625% Senior Notes due 2025 on September 29, 2025, contingent upon the completion of the new notes issuance. The redemption will occur at 100% of the principal amount plus accrued interest. Notice of this redemption will be communicated to registered holders by the Paying Agent, and further details can be obtained from them.

Sep 16, 2025 16:41:16

Medtronic Reports First Quarter Fiscal 2026 Financial Results

Medtronic plc announced its financial results for the first quarter of fiscal year 2026, reporting revenue of $8.6 billion, which represents an 8.4% increase compared to the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $0.81, marking a 1% increase, while the non-GAAP diluted EPS rose by 2% to $1.26. The growth was driven by a nearly 50% increase in revenue from Cardiac Ablation Solutions, particularly in the U.S., alongside solid performances in other key product categories including Neuromodulation and Diabetes. Medtronic reiterated its guidance for organic revenue growth of approximately 5% for the fiscal year and raised its diluted non-GAAP EPS guidance to a range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60.

Additionally, Medtronic's Board of Directors expanded from 11 to 13 members, appointing John Groetelaars and William Jellison as new directors. Both will serve on the newly formed Growth committee, with Jellison also joining the Operations committee. Their appointments are part of the company's ongoing efforts to enhance governance and drive growth. The company is focused on accelerating revenue growth in the second half of the fiscal year while increasing investments in research and development, sales, and marketing to foster long-term shareholder value.

Aug 19, 2025 06:49:43

Medtronic Appoints Dr. Joon Lee as New Board Director

Medtronic plc has appointed Dr. Joon Lee, the CEO of Emory Healthcare, Inc., as an independent director of its Board, effective June 18, 2025. Dr. Lee will contribute to the Science and Technology Committee and Compensation and Talent Committee. His extensive background includes over 25 years at the University of Pittsburgh Medical Center, where he held significant leadership roles, including Executive Vice President and President of Physician Services.

Dr. Lee is recognized for his expertise in interventional cardiology and healthcare management. He has overseen a major health system with substantial revenue and a large workforce. His experience includes managing patient services and financial oversight, along with roles in academic medicine and clinical affairs. Dr. Lee's appointment may influence Medtronic's strategic direction and operational focus in healthcare technology.

Jun 23, 2025 16:17:20

Medtronic Announces Dividend Increase and Business Separation Plans

Medtronic plc reported its fourth quarter and fiscal year 2025 financial results, showing a revenue increase of 3.9% in Q4, totaling $8.9 billion, and a fiscal year revenue of $33.5 billion, up 3.6%. The company also reported significant increases in earnings per share, with Q4 GAAP EPS rising 67% to $0.82 and fiscal year GAAP EPS increasing 31% to $3.61. Medtronic returned $6.3 billion to shareholders in FY25 and announced a dividend increase to $0.71 per share for Q1 FY26, marking the 48th consecutive year of dividend increases. Additionally, the company plans to separate its Diabetes business into a standalone public company within 18 months, which may impact future financial performance and shareholder value.

The company highlighted strong performance in its key franchises, including significant growth in Cardiac Ablation Solutions, which reported nearly 30% revenue growth in Q4. Medtronic also received FDA approval for several products, including the Hugo™ robotic-assisted surgery system and BrainSense™ Adaptive Deep Brain Stimulation technology. The leadership transition in the Cardiovascular Portfolio was also announced, with Skip Kiil promoted to executive vice president. Overall, Medtronic's operational metrics indicate a solid foundation for future growth, supported by ongoing investments in its key growth drivers.

May 21, 2025 06:47:23

Medtronic Q3 FY25 Revenue Grows 2.5% with Mixed Results

Medtronic reported a revenue increase of 2.5% for the third quarter of fiscal year 2025, totaling $8.3 billion, with organic growth at 4.1%. Notable growth was seen in the Cardiovascular and Diabetes portfolios, with Cardiac Ablation Solutions revenue rising significantly due to the popularity of pulsed field ablation products. The company also benefited from a recent approval for Renal Denervation coverage, which is expected to enhance future revenue potential in hypertension treatment. Additionally, non-GAAP diluted EPS increased by 7% to $1.39, reflecting improved earnings performance.

However, there were some negative aspects in the report, particularly in the Medical Surgical Portfolio, which experienced a revenue decline of 1.9% as reported and 0.4% on an organic basis. This decline was attributed to pressures in the stapling segment and a decrease in respiratory-related hospitalizations impacting blood oxygen management products. The overall performance of the Neuroscience and Medical Surgical segments showed mixed results, with certain areas underperforming despite gains in other divisions.

Feb 18, 2025 06:46:40

Medtronic Appoints Thierry Piéton as CFO Effective March 2025

Medtronic has announced the appointment of Thierry Piéton as Chief Financial Officer, effective March 3, 2025. Piéton previously served as CFO at Renault Group, where he achieved significant operational improvements and shareholder value. His extensive experience in various industries, including healthcare, positions him to lead Medtronic's global finance organization effectively. Gary Corona, the interim CFO, will transition to a new role as Senior Vice President, Corporate Finance, after Piéton's arrival.

While recognizing the contributions of Gary Corona in delivering revenue growth and exceeding earnings expectations, the transition to a new CFO represents a significant change for Medtronic. The company is poised for a new leadership direction under Piéton, which may bring uncertainties as he integrates into the organization and implements his strategies. Medtronic's future financial performance will depend on how effectively Piéton navigates these changes.

Jan 21, 2025 06:51:55

Medtronic Reports $8.4 Billion Revenue in Q2 FY25

Medtronic announced its financial results for the second quarter of fiscal year 2025, reporting a revenue of $8.4 billion, which reflects a 5.3% increase compared to the previous year. The company also noted significant growth in various segments, including a 12.4% rise in its Diabetes division and a 6.1% increase in its Cardiovascular Portfolio. Additionally, Medtronic raised its guidance for organic revenue growth and diluted non-GAAP earnings per share (EPS) for the fiscal year, indicating positive momentum across its business operations.

However, not all aspects of the report were favorable. While GAAP net income and diluted EPS showed substantial increases of 40% and 46%, respectively, the non-GAAP diluted EPS experienced a slight decline of 3%. The Medical Surgical Portfolio reported only a 1.2% increase in revenue, with some divisions, like Surgical & Endoscopy, facing flat organic growth. Furthermore, foreign currency translation negatively impacted the non-GAAP EPS by 9 cents, highlighting potential challenges amid global market fluctuations.

Nov 19, 2024 06:46:38